- Home
- INSW vs INDV Comparison
INSW vs INDV Comparison
Compare INSW & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSW | INDV |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.4B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INSW | INDV |
|---|---|---|
| Price | $81.07 | $37.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $77.00 | N/A |
| AVG Volume (30 Days) | 515.5K | ★ 1.6M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | ★ 5.75 | 0.69 |
| Revenue | $843,302,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.61 | $54.28 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $36.03 | $13.42 |
| 52 Week High | $92.66 | $41.00 |
Technical Indicators
Market Signals| Indicator | INSW | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 57.67 |
| Support Level | $75.08 | $35.36 |
| Resistance Level | $92.66 | $38.08 |
| Average True Range (ATR) | 2.77 | 1.38 |
| MACD | -0.78 | -0.20 |
| Stochastic Oscillator | 47.59 | 89.13 |
Price Performance
Historical ComparisonAbout INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. Its fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).